Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations

被引:0
|
作者
Coutinho, Anna D. [1 ]
Raju, Aditya D. [1 ]
Wang, Weijia [2 ]
Stafkey-Mailey, Dana [1 ]
Shetty, Sharash [2 ]
Sander, Stephen D. [2 ]
机构
[1] Xcenda LLC, Palm Harbor, FL USA
[2] Boehringer Ingelhe Pharmaceut Inc, Ridgefield, CT USA
关键词
Cardiovascular disease; hospitalization; healthcare resource utilization; healthcare costs; observational studies; HEART-DISEASE; ALL-CAUSE; OUTCOMES; MORTALITY; WOMEN; MEN; MELLITUS; FAILURE; RISK;
D O I
10.1080/03007995.2018.1434497
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the incremental economic burden of type 2 diabetes in patients experiencing cardiovascular (CV) hospitalizations. Research design and methods: Adults with >= 1 CV hospitalization were identified using a US-based healthcare claims database from 1 July 2011 to 30 June 2014. Outcomes for patients surviving the index hospitalization were compared between patients with vs. without type 2 diabetes (cohorts were identified in the pre-index period). Subsequent CV hospitalizations were evaluated using Cox proportional hazards models. All-cause and CV-related healthcare resource utilization (HCRU) and costs captured on a per-patient per-month (PPPM) basis during a variable follow-up period were evaluated using appropriate multivariable regression models. Results: Of 316,207 patients with >= 1 CV hospitalization, 23% had comorbid type 2 diabetes. The mean age +/- SD was 62.6 +/- 12.3 years and 64.4% were male. During follow-up, the type 2 diabetes cohort had a 19% higher risk of subsequent CV hospitalizations compared to the non-type-2-diabetes cohort (p <.001). This difference in risk was highest in patients aged 35-44 years. Subsequent all-cause hospitalizations for the type 2 diabetes cohort were longer (mean length of stay, 6.7 vs. 6.3 days; p <.001), with higher total bed-days PPPM (mean, 0.52 vs. 0.43; p <.001), compared to the non-type-2-diabetes cohort. The type 2 diabetes cohort had a significantly higher incremental cost for both the index CV hospitalization (mean cost difference, $1046; p <.001) and all-cause costs PPPM following discharge (mean cost difference, $749; p < .001). Conclusions: Comorbid type 2 diabetes was associated with an increased risk of subsequent CV hospitalizations and higher costs and HCRU during the follow-up period.
引用
收藏
页码:1005 / 1012
页数:8
相关论文
共 50 条
  • [41] Cardiovascular Outcomes with Dapagliflozin for Patients with Type 2 Diabetes
    Pavlicek, Vojtech
    [J]. DIABETOLOGE, 2019, 15 (03): : 262 - 264
  • [42] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Cosmi, Franco
    Latini, Roberto
    Nicolucci, Antonio
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09): : 890 - 890
  • [43] Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes
    Al-Bazz, Dalai Y.
    Wilding, John P. H.
    [J]. FUTURE CARDIOLOGY, 2020, 16 (02) : 77 - 88
  • [44] Estimation of Cardiovascular Risk in Patients with Type 2 Diabetes
    Vicente Sanchez, Belkis
    Vicente Pena, Ernesto
    Costa Cruz, Miriam
    [J]. FINLAY, 2015, 5 (03): : 178 - 188
  • [45] Cardiovascular risk stratification in patients with type 2 diabetes
    Grossmann, V.
    Schmitt, V. H.
    Juenger, C.
    Muenzel, T.
    Wild, P. S.
    [J]. DIABETOLOGE, 2014, 10 (07): : 572 - 580
  • [47] The burden of cardiovascular outcomes in heart failure patients with new-onset, prevalent, and without type 2 diabetes
    Bochra Zareini
    Paul Blanche
    Anders Holt
    Mariam Elmegaard Malik
    Christian Selmer
    Gunnar Gislason
    Søren Lund Kristensen
    Lars Køber
    Christian Torp-Pedersen
    Morten Schou
    Morten Lamberts
    [J]. Clinical Research in Cardiology, 2022, 111 : 460 - 468
  • [48] Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease
    McGuire, D.
    Zinman, B.
    Inzucchi, S. E.
    Anker, S. D.
    Wanner, C.
    Kaspers, S.
    Von Eynatten, M.
    Johansen, O-E.
    Elsasser, U.
    Pocock, S.
    Fitchett, D.
    Jamal, W.
    Hantel, S.
    Lund, S. S.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 3875 - 3875
  • [49] The burden of cardiovascular outcomes in heart failure patients with new-onset, prevalent, and without type 2 diabetes
    Zareini, Bochra
    Blanche, Paul
    Holt, Anders
    Malik, Mariam Elmegaard
    Selmer, Christian
    Gislason, Gunnar
    Kristensen, Soren Lund
    Kober, Lars
    Torp-Pedersen, Christian
    Schou, Morten
    Lamberts, Morten
    [J]. CLINICAL RESEARCH IN CARDIOLOGY, 2022, 111 (04) : 460 - 468
  • [50] Humanistic and economic burden of cardiovascular disease related comorbidities and hypoglycaemia among patients with type 2 diabetes in Japan
    Terauchi, Yasuo
    Ozaki, Asuka
    Zhao, Xiahong
    Teoh, Cheryl
    Jaffe, Dena
    Tajima, Yuki
    Shuto, Yujin
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 149 : 115 - 125